{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:46:47Z","timestamp":1791287207586,"version":"4.1.0"},"reference-count":137,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Patients with rosacea commonly experience stigmatization, which induces stress and thereby exacerbates their symptoms. Given the strong effects of rosacea on health-related quality of life (HRQoL), addressing the physical and psychosocial aspects of rosacea is essential. To examine the effects of rosacea on HRQoL, we conducted a systematic review and meta-analysis involving real-world data. PubMed, EMBASE, and the Cochrane Library were searched, and randomized controlled trials (RCTs), cross-sectional studies, and case series evaluating the HRQoL of patients with rosacea were included. HRQoL assessment tools such as the Dermatology Life Quality Index (DLQI) and Rosacea-Specific Quality-of-Life Questionnaire (RosaQoL) were used. Data on 13,453 patients were retrieved from 52 eligible studies: 4 RCTs, 15 case series, and 33 cross-sectional studies. Compared with healthy controls, patients with rosacea had significantly lower DLQI scores (standardized mean difference [SMD]\u2009=\u2009\u22121.09, 95% confidence interval [CI]\u2009=\u2009\u22120.81 to \u22121.37). The DLQI scores after treatment were higher than those before treatment (SMD\u2009=\u2009\u22121.451, 95% CI\u2009=\u2009\u22121.091 to \u22121.810). The pooled estimates for the overall DLQI and RosaQoL scores were 8.61 and 3.06, respectively. In conclusion, patients with rosacea have lower HRQoL compared with healthy individuals, and treatment for rosacea improves their HRQoL.<\/jats:p>","DOI":"10.2340\/actadv.v104.40053","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T10:00:15Z","timestamp":1719309615000},"page":"adv40053","source":"Crossref","is-referenced-by-count":12,"title":["Health-related Quality of Life of Patients with Rosacea: A Systematic Review and Meta-analysis of Real-world Data"],"prefix":"10.2340","volume":"104","author":[{"given":"Ching-Wen","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"67213","doi-asserted-by":"crossref","unstructured":"Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46: 584-587.","DOI":"10.1067\/mjd.2002.120625"},{"key":"67214","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1067\/mjd.2002.120625","DOI":"10.1067\/mjd.2002.120625"},{"key":"67215","doi-asserted-by":"crossref","unstructured":"Tan J, Blume-Peytavi U, Ortonne JP, Wilhelm K, Marticou L, Baltas E, et al. An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes. Br J Dermatol 2013; 169: 555-562.","DOI":"10.1111\/bjd.12385"},{"key":"67216","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.12385","DOI":"10.1111\/bjd.12385"},{"key":"67217","doi-asserted-by":"crossref","unstructured":"Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol 2013; 69: S27-S35.","DOI":"10.1016\/j.jaad.2013.04.043"},{"key":"67218","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2013.04.043","DOI":"10.1016\/j.jaad.2013.04.043"},{"key":"67219","doi-asserted-by":"crossref","unstructured":"Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol 2018; 179: 282-289.","DOI":"10.1111\/bjd.16481"},{"key":"67220","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.16481","DOI":"10.1111\/bjd.16481"},{"key":"67221","doi-asserted-by":"crossref","unstructured":"Van Beugen S, Schut C, Kupfer J, Bewley AP, Finlay AY, Gieler U, et al. Perceived stigmatization among dermatological outpatients compared with controls: an observational multicentre study in 17 European countries. Acta Derm Venereol 2023; 103: adv6485.","DOI":"10.2340\/actadv.v103.6485"},{"key":"67222","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/actadv.v103.6485","DOI":"10.2340\/actadv.v103.6485"},{"key":"67223","doi-asserted-by":"crossref","unstructured":"Chang HC, Huang YC, Lien YJ, Chang YS. Association of rosacea with depression and anxiety: a systematic review and meta-analysis. J Affect Disord 2022; 299: 239-245.","DOI":"10.1016\/j.jad.2021.12.008"},{"key":"67224","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jad.2021.12.008","DOI":"10.1016\/j.jad.2021.12.008"},{"key":"67225","doi-asserted-by":"crossref","unstructured":"van Zuuren EJ, Graber MA, Hollis S, Chaudhry M, Gupta AK, Gover M. Interventions for rosacea. Cochrane Database Syst Rev 2005: Cd003262.","DOI":"10.1002\/14651858.CD003262.pub3"},{"key":"67226","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/14651858.CD003262.pub3","DOI":"10.1002\/14651858.CD003262.pub3"},{"key":"67227","doi-asserted-by":"crossref","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"67228","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"67229","doi-asserted-by":"crossref","unstructured":"Nicholson K, Abramova L, Chren MM, Yeung J, Chon SY, Chen SC. A pilot quality-of-life instrument for acne rosacea. J Am Acad Dermatol 2007; 57: 213-221.","DOI":"10.1016\/j.jaad.2007.01.048"},{"key":"67230","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2007.01.048","DOI":"10.1016\/j.jaad.2007.01.048"},{"key":"67231","doi-asserted-by":"crossref","unstructured":"Renzi C, Tabolli S, Picardi A, Abeni D, Puddu P, Braga M. Effects of patient satisfaction with care on health-related quality of life: a prospective study. J Eur Acad Dermatol Venereol 2005; 19: 712-718.","DOI":"10.1111\/j.1468-3083.2005.01301.x"},{"key":"67232","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2005.01301.x","DOI":"10.1111\/j.1468-3083.2005.01301.x"},{"key":"67233","doi-asserted-by":"crossref","unstructured":"Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001; 5: 105-110.","DOI":"10.1177\/120347540100500202"},{"key":"67234","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/120347540100500202","DOI":"10.1177\/120347540100500202"},{"key":"67235","doi-asserted-by":"crossref","unstructured":"Luger T, Peukert N, Rother M. A multicentre, randomized, placebo-controlled trial establishing the treatment effect of TDT 068, a topical formulation containing drug-free ultra-deformable phospholipid vesicles, on the primary features of erythematotelangiectatic rosacea. J Eur Acad Dermatol Venereol 2015; 29: 283-290.","DOI":"10.1111\/jdv.12520"},{"key":"67236","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.12520","DOI":"10.1111\/jdv.12520"},{"key":"67237","doi-asserted-by":"crossref","unstructured":"van der Linden MMD, van Ratingen AR, van Rappard DC, Nieuwenburg SA, Spuls PI. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety. Br J Dermatol 2017; 176: 1465-1474.","DOI":"10.1111\/bjd.15155"},{"key":"67238","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.15155","DOI":"10.1111\/bjd.15155"},{"key":"67239","doi-asserted-by":"crossref","unstructured":"van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for rosacea. Cochrane Database Syst Rev 2015; 2015: Cd003262.","DOI":"10.1002\/14651858.CD003262.pub5"},{"key":"67240","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/14651858.CD003262.pub5","DOI":"10.1002\/14651858.CD003262.pub5"},{"key":"67241","doi-asserted-by":"crossref","unstructured":"van der Linden MM, van Rappard DC, Daams JG, Sprangers MA, Spuls PI, de Korte J. Health-related quality of life in patients with cutaneous rosacea: a systematic review. Acta Derm Venereol 2015; 95: 395-400.","DOI":"10.2340\/00015555-1976"},{"key":"67242","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1976","DOI":"10.2340\/00015555-1976"},{"key":"67243","doi-asserted-by":"crossref","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1-34.","DOI":"10.1016\/j.jclinepi.2009.06.006"},{"key":"67244","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jclinepi.2009.06.006","DOI":"10.1016\/j.jclinepi.2009.06.006"},{"key":"67245","unstructured":"Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. Ottawa Hospital Research Institute; 2000."},{"key":"67246","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane; 2023. Available from www.training.cochrane.org\/handbook."},{"key":"67247","doi-asserted-by":"crossref","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919.","DOI":"10.1136\/bmj.i4919"},{"key":"67248","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmj.i4919","DOI":"10.1136\/bmj.i4919"},{"key":"67249","unstructured":"Rostom A, Dub\u00e9 C, Cranney A, Saloojee N, Sy R, Garritty C, et al. Celiac disease. Rockville (MD): Agency for Healthcare Research and Quality (US); 2004 Sep. (evidence Reports\/Technology assessments, no. 104). Appendix D: quality assessment forms; 2014."},{"key":"67250","doi-asserted-by":"crossref","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials 2015; 45: 139-145.","DOI":"10.1016\/j.cct.2015.09.002"},{"key":"67251","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.cct.2015.09.002","DOI":"10.1016\/j.cct.2015.09.002"},{"key":"67252","doi-asserted-by":"crossref","unstructured":"Acar EM, Kaya Erdo\u011fan H, \u015ea\u015f S, Acer E. Evaluation of fibromyalgia syndrome in patients with rosacea. Arch Rheumatol 2021; 36: 252-257.","DOI":"10.46497\/ArchRheumatol.2021.8280"},{"key":"67253","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.46497\/ArchRheumatol.2021.8280","DOI":"10.46497\/ArchRheumatol.2021.8280"},{"key":"67254","doi-asserted-by":"crossref","unstructured":"Augustin M, Sommer R, Blome C, Kirsten N, Langenbruch A. Development of a specific variant of Patient Benefit Index (PBI) assessing patient needs, goals and benefits in rosacea treatment. Patient Prefer Adherence 2023; 17: 1335-1345.","DOI":"10.2147\/PPA.S378724"},{"key":"67255","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/PPA.S378724","DOI":"10.2147\/PPA.S378724"},{"key":"67256","doi-asserted-by":"crossref","unstructured":"Azrumelashvili S, Kituashvili T. Quality of life and disease coping strategies in patients with rosacea. Georgian Med News 2023; 336: 66-72.","DOI":"10.21203\/rs.3.rs-1995071\/v1"},{"key":"67257","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.21203\/rs.3.rs-1995071\/v1","DOI":"10.21203\/rs.3.rs-1995071\/v1"},{"key":"67258","unstructured":"Boehncke WH, Ochsendorf F, Paeslack I, Kaufmann R, Zollner TM. Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases. Eur J Dermatol 2002; 12: 577-580."},{"key":"67259","doi-asserted-by":"crossref","unstructured":"B\u00f6hm D, Schwanitz P, Stock Gissendanner S, Schmid-Ott G, Schulz W. Symptom severity and psychological sequelae in rosacea: results of a survey. Psychol Health Med 2014; 19: 586-591.","DOI":"10.1080\/13548506.2013.841968"},{"key":"67260","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/13548506.2013.841968","DOI":"10.1080\/13548506.2013.841968"},{"key":"67261","doi-asserted-by":"crossref","unstructured":"Bribeche MR, Fedotov VP, Gladichev VV, Pukhalskaya DM, Kolitcheva NL. Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea. Int J Dermatol 2015; 54: 481-487.","DOI":"10.1111\/ijd.12552"},{"key":"67262","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ijd.12552","DOI":"10.1111\/ijd.12552"},{"key":"67263","doi-asserted-by":"crossref","unstructured":"Bulbul Baskan E, Akin Belli A. Evaluation of long-term efficacy, safety, and effect on life quality of pulsed dye laser in rosacea patients. J Cosmet Laser Ther 2019; 21: 185-189.","DOI":"10.1080\/14764172.2018.1502453"},{"key":"67264","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/14764172.2018.1502453","DOI":"10.1080\/14764172.2018.1502453"},{"key":"67265","doi-asserted-by":"crossref","unstructured":"Campos MA, Sousa AC, Varela P, Baptista A, Menezes N. Comparative effectiveness of purpuragenic 595 nm pulsed dye laser versus sequential emission of 595 nm pulsed dye laser and 1,064 nm Nd:YAG laser: a double-blind randomized controlled study. Acta Dermatovenerol Alp Pannonica Adriat 2019; 28: 1-5.","DOI":"10.15570\/actaapa.2019.1"},{"key":"67266","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.15570\/actaapa.2019.1","DOI":"10.15570\/actaapa.2019.1"},{"key":"67267","doi-asserted-by":"crossref","unstructured":"Chen M, Deng Z, Huang Y, Li J. Prevalence and risk factors of anxiety and depression in rosacea patients: a cross-sectional study in China. Front Psychiatry 2021; 12: 659171.","DOI":"10.3389\/fpsyt.2021.659171"},{"key":"67268","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fpsyt.2021.659171","DOI":"10.3389\/fpsyt.2021.659171"},{"key":"67269","unstructured":"Fleischer A, Suephy C. The face and mind evaluation study: an examination of the efficacy of rosacea treatment using physician ratings and patients' self-reported quality of life. J Drugs Dermatol 2005; 4: 585-590."},{"key":"67270","doi-asserted-by":"crossref","unstructured":"Friedman O, Koren A, Niv R, Mehrabi JN, Artzi O. The toxic edge: a novel treatment for refractory erythema and flushing of rosacea. Lasers Surg Med 2019; 51: 325-331.","DOI":"10.1002\/lsm.23023"},{"key":"67271","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/lsm.23023","DOI":"10.1002\/lsm.23023"},{"key":"67272","unstructured":"Harper J, Del Rosso JQ, Ferrusi IL. Cross-sectional survey of the burden of illness of rosacea by erythema severity. J Drugs Dermatol 2018; 17: 150-158."},{"key":"67273","doi-asserted-by":"crossref","unstructured":"Huang Y, Yan S, Xie H, Wang B, Zhao Z, Huang Y, et al. Health related quality of life of rosacea patients in China assessed by dermatology life quality index and willingness to pay. Patient Prefer Adherence 2022; 16: 659-670.","DOI":"10.2147\/PPA.S345258"},{"key":"67274","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/PPA.S345258","DOI":"10.2147\/PPA.S345258"},{"key":"67275","doi-asserted-by":"crossref","unstructured":"Kini SP, Nicholson K, DeLong LK, Dannemann T, Estaris J, Foster J, et al. A pilot study in discrepancies in quality of life among three cutaneous types of rosacea. J Am Acad Dermatol 2010; 62: 1069-1071.","DOI":"10.1016\/j.jaad.2009.08.020"},{"key":"67276","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2009.08.020","DOI":"10.1016\/j.jaad.2009.08.020"},{"key":"67277","doi-asserted-by":"crossref","unstructured":"Kubanov A, Gallyamova Y, Kravchenko A. Clinical picture, diagnosis and treatment of rosacea, complicated by Demodex mites. Dermatol Reports 2019; 11: 7675.","DOI":"10.4081\/dr.2019.7675"},{"key":"67278","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.4081\/dr.2019.7675","DOI":"10.4081\/dr.2019.7675"},{"key":"67279","doi-asserted-by":"crossref","unstructured":"Kulakl\u0131 S, O\u011fuz ID, Sar\u0131 IF, Sengul I, Kulakl\u0131 F, Ak\u015fan B, et al. \"Zooming\" in the association between rosacea and fibromyalgia syndrome: is it worth mentioning? Rev Assoc Med Bras (1992) 2023; 69: e20230256.","DOI":"10.1590\/1806-9282.20230256"},{"key":"67280","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1590\/1806-9282.20230256","DOI":"10.1590\/1806-9282.20230256"},{"key":"67281","doi-asserted-by":"crossref","unstructured":"Langenbruch AK, Beket E, Augustin M. Quality of health care of rosacea in Germany from the patient's perspective: results of the national health care study Rosareal 2009. Dermatology 2011; 223: 124-130.","DOI":"10.1159\/000330555"},{"key":"67282","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000330555","DOI":"10.1159\/000330555"},{"key":"67283","doi-asserted-by":"crossref","unstructured":"Li J, Li M, Chen Q, Fu J, Zhang M, Hao F. Quality of life among patients with rosacea: an investigation of patients in China using two structured questionnaires. J Eur Acad Dermatol Venereol 2016; 30: e98-e99.","DOI":"10.1111\/jdv.13341"},{"key":"67284","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.13341","DOI":"10.1111\/jdv.13341"},{"key":"67285","doi-asserted-by":"crossref","unstructured":"Menezes N, Moreira A, Mota G, Baptista A. Quality of life and rosacea: pulsed dye laser impact. J Cosmet Laser Ther 2009; 11: 139-141.","DOI":"10.1080\/14764170902741311"},{"key":"67286","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/14764170902741311","DOI":"10.1080\/14764170902741311"},{"key":"67287","doi-asserted-by":"crossref","unstructured":"Ozcan Y, Sungur MA, Ozcan BY, Eyup Y, Ozlu E. The psychosocial impact of chronic facial dermatoses in adults. Dermatol Pract Concept 2023; 13: e2023029.","DOI":"10.5826\/dpc.1301a29"},{"key":"67288","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5826\/dpc.1301a29","DOI":"10.5826\/dpc.1301a29"},{"key":"67289","unstructured":"Salamon M, Chodkiewicz J, Sysa-Jedrzejowska A, Wozniacka A. [Quality of life in patients with rosacea]. Przegl Lek 2008; 65: 385-389 (in Polish)."},{"key":"67290","doi-asserted-by":"crossref","unstructured":"Sbidian E, Vicaut \u00c9, Chidiack H, Anselin E, Cribier B, Dr\u00e9no B, et al. A randomized-controlled trial of oral low-dose isotretinoin for difficult-to-treat papulopustular rosacea. J Invest Dermatol 2016; 136: 1124-1129.","DOI":"10.1016\/j.jid.2016.01.025"},{"key":"67291","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2016.01.025","DOI":"10.1016\/j.jid.2016.01.025"},{"key":"67292","doi-asserted-by":"crossref","unstructured":"Schaller M, Dirschka T, Kem\u00e9ny L, Briantais P, Jacovella J. Superior efficacy with ivermectin 1% cream compared to metronidazole 0.75% cream contributes to a better quality of life in patients with severe papulopustular rosacea: a subanalysis of the randomized, investigator-blinded ATTRACT study. Dermatol Ther (Heidelb) 2016; 6: 427-436.","DOI":"10.1007\/s13555-016-0133-6"},{"key":"67293","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-016-0133-6","DOI":"10.1007\/s13555-016-0133-6"},{"key":"67294","unstructured":"Shim TN, Abdullah A. The effect of pulsed dye laser on the dermatology life quality index in erythematotelangiectatic rosacea patients: an assessment. J Clin Aesthet Dermatol 2013; 6: 30-32."},{"key":"67295","doi-asserted-by":"crossref","unstructured":"Taieb A, Passeron T, Ruzicka T, Berth-Jones J, Jacovella J, Huang MY, et al. Ivermectin cream improves health-related quality of life in patients with rosacea: data from a randomized trial. Br J Dermatol 2016; 175: 1366-1368.","DOI":"10.1111\/bjd.14665"},{"key":"67296","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.14665","DOI":"10.1111\/bjd.14665"},{"key":"67297","doi-asserted-by":"crossref","unstructured":"Tan SR, Tope WD. Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life. J Am Acad Dermatol 2004; 51: 592-599.","DOI":"10.1016\/j.jaad.2004.04.010"},{"key":"67298","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2004.04.010","DOI":"10.1016\/j.jaad.2004.04.010"},{"key":"67299","doi-asserted-by":"crossref","unstructured":"Thomas CL, Kim B, Lam J, Richards S, See A, Kalouche S, et al. Objective severity does not capture the impact of rosacea, acne scarring and photoaging in patients seeking laser therapy. J Eur Acad Dermatol Venereol 2017; 31: 361-366.","DOI":"10.1111\/jdv.13945"},{"key":"67300","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.13945","DOI":"10.1111\/jdv.13945"},{"key":"67301","unstructured":"Trumbore MW, Goldstein JA, Gurge RM. Treatment of papulopustular rosacea with sodium sulfacetamide 10%\/sulfur 5% emollient foam. J Drugs Dermatol 2009; 8: 299-304."},{"key":"67302","unstructured":"Tyring S, Solomon JA, Staedtler G, Lott JP, Nkulikiyinka R, Shakery K. Patient-reported outcomes of azelaic acid foam 15% for patients with papulopustular rosacea: secondary efficacy results from a randomized, controlled, double-blind, phase 3 trial. Cutis 2016; 98: 269-275."},{"key":"67303","doi-asserted-by":"crossref","unstructured":"Wang B, Deng YX, Li PY, Yan S, Xie HF, Li J, et al. Efficacy and safety of non-insulated fractional microneedle radiofrequency for treating difficult-to-treat rosacea: a 48-week, prospective, observational study. Arch Dermatol Res 2022; 314: 643-650.","DOI":"10.1007\/s00403-021-02259-2"},{"key":"67304","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00403-021-02259-2","DOI":"10.1007\/s00403-021-02259-2"},{"key":"67305","doi-asserted-by":"crossref","unstructured":"Wang B, Deng YX, Yan S, Xie HF, Li J, Jian D. Efficacy of non-ablative fractional 1440-nm laser therapy for treatment of facial acne scars in patients with rosacea: a prospective, interventional study. Lasers Med Sci 2021; 36: 649-655.","DOI":"10.1007\/s10103-020-03107-x"},{"key":"67306","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10103-020-03107-x","DOI":"10.1007\/s10103-020-03107-x"},{"key":"67307","doi-asserted-by":"crossref","unstructured":"Wang T, Liu F, Jia X, Tan J, Qi B, Guo J, et al. Serum level of brain-derived neurotrophic factor (BDNF) associated with depression in patients with rosacea: a candidate predictive biomarker. Clin Cosmet Investig Dermatol 2022; 15: 1029-1036.","DOI":"10.2147\/CCID.S367545"},{"key":"67308","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CCID.S367545","DOI":"10.2147\/CCID.S367545"},{"key":"67309","doi-asserted-by":"crossref","unstructured":"Weissenbacher S, Merkl J, Hildebrandt B, Wollenberg A, Braeutigam M, Ring J, et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol 2007; 156: 728-732.","DOI":"10.1111\/j.1365-2133.2006.07669.x"},{"key":"67310","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07669.x","DOI":"10.1111\/j.1365-2133.2006.07669.x"},{"key":"67311","doi-asserted-by":"crossref","unstructured":"Wienholtz NKF, Christensen CE, Haugaard JH, Zhang DG, Ashina M, Thyssen JP, et al. Cohort profile: COpenhagen ROsacea COhort (COROCO) and COpenhagen MIgraine COhort (COMICO). BMJ Open 2020; 10: e039445.","DOI":"10.1136\/bmjopen-2020-039445"},{"key":"67312","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmjopen-2020-039445","DOI":"10.1136\/bmjopen-2020-039445"},{"key":"67313","doi-asserted-by":"crossref","unstructured":"Williamson T, Cameron J, McLeod K, Turner B, Quillen A, LaRose A, et al. Concerns and treatment satisfaction in patients being treated with azelaic acid foam for rosacea. J Drugs Dermatol 2019;18: 381-386.","DOI":"10.25251\/skin.2.supp.35"},{"key":"67314","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.25251\/skin.2.supp.35","DOI":"10.25251\/skin.2.supp.35"},{"key":"67315","unstructured":"Williamson T, Cheng WY, McCormick N, Vekeman F. Patient preferences and therapeutic satisfaction with topical agents for rosacea: a survey-based study. Am Health Drug Benefits 2018; 11: 97-106."},{"key":"67316","doi-asserted-by":"crossref","unstructured":"Wu Y, Fu C, Zhang W, Li C, Zhang J. The dermatology life quality index (DLQI) and the hospital anxiety and depression (HADS) in Chinese rosacea patients. Psychol Health Med 2018;23: 369-374.","DOI":"10.1080\/13548506.2017.1361540"},{"key":"67317","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/13548506.2017.1361540","DOI":"10.1080\/13548506.2017.1361540"},{"key":"67318","doi-asserted-by":"crossref","unstructured":"Yang F, Zhang Q, Song D, Liu X, Wang L, Jiang X. A cross-sectional study on the relationship between rosacea severity and quality of life or psychological state. Clin Cosmet Investig Dermatol 2022; 15: 2807-2816.","DOI":"10.2147\/CCID.S390921"},{"key":"67319","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CCID.S390921","DOI":"10.2147\/CCID.S390921"},{"key":"67320","doi-asserted-by":"crossref","unstructured":"Yang J, Liu X, Cao Y, Wang P, Zhang H, Chen Q, et al. 5-aminolevulinic acid photodynamic therapy versus minocycline for moderate to severe rosacea: a single-center, randomized, evaluator-blind controlled study. J Am Acad Dermatol 2023; 89: 711-718.","DOI":"10.1016\/j.jaad.2023.06.027"},{"key":"67321","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2023.06.027","DOI":"10.1016\/j.jaad.2023.06.027"},{"key":"67322","doi-asserted-by":"crossref","unstructured":"Yang R, Liu C, Liu W, Luo J, Cheng S, Mu X. Botulinum toxin A alleviates persistent erythema and flushing in patients with erythema telangiectasia rosacea. Dermatol Ther (Heidelb) 2022; 12: 2285-2294.","DOI":"10.1007\/s13555-022-00784-0"},{"key":"67323","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-022-00784-0","DOI":"10.1007\/s13555-022-00784-0"},{"key":"67324","doi-asserted-by":"crossref","unstructured":"Yang TT, Lan CE. Impacts of skin disorders associated with facial discoloration on quality of life: novel insights explaining discordance between life quality scores and willingness to pay. J Cosmet Dermatol 2022; 21: 3053-3058.","DOI":"10.1111\/jocd.14546"},{"key":"67325","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jocd.14546","DOI":"10.1111\/jocd.14546"},{"key":"67326","unstructured":"Zeichner JA, Eichenfield LF, Feldman SR, Kasteler JS, Ferrusi IL. Quality of life in individuals with erythematotelangiectatic and papulopustular rosacea: findings from a web-based survey. J Clin Aesthet Dermatol 2018; 11: 47-52."},{"key":"67327","doi-asserted-by":"crossref","unstructured":"Hiltscher D, Boslet WT, Fuchslocher M, Sinkgraven R, Rzany B. Quality of life in patients with rosacea and rhinophyma. Aktuelle Derm 2001; 27: 391-394.","DOI":"10.1055\/s-2001-19630"},{"key":"67328","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1055\/s-2001-19630","DOI":"10.1055\/s-2001-19630"},{"key":"67329","doi-asserted-by":"crossref","unstructured":"Tan J, Steinhoff M, Bewley A, Gieler U, Rives V. Characterizing high-burden rosacea subjects: a multivariate risk factor analysis from a global survey. J Dermatol Treat 2020; 31: 168-174.","DOI":"10.1080\/09546634.2019.1623368"},{"key":"67330","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2019.1623368","DOI":"10.1080\/09546634.2019.1623368"},{"key":"67331","doi-asserted-by":"crossref","unstructured":"Wang B, Yuan X, Huang X, Tang Y, Zhao Z, Yang B, et al. Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: a multicenter, randomized, double-blind, double-dummy, pilot study. J Am Acad Dermatol 2021; 84: 543-545.","DOI":"10.1016\/j.jaad.2020.05.050"},{"key":"67332","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.05.050","DOI":"10.1016\/j.jaad.2020.05.050"},{"key":"67333","doi-asserted-by":"crossref","unstructured":"Yamasaki K, Miyachi Y. Perspectives on rosacea patient characteristics and quality of life using baseline data from a phase 3 clinical study conducted in Japan. J Dermatol 2022; 49: 1221-1227.","DOI":"10.1111\/1346-8138.16596"},{"key":"67334","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/1346-8138.16596","DOI":"10.1111\/1346-8138.16596"},{"key":"67335","doi-asserted-by":"crossref","unstructured":"Aksoy B, Altaykan-Hapa A, Egemen D, Karag\u00f6z F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol 2010; 163: 719-725.","DOI":"10.1111\/j.1365-2133.2010.09894.x"},{"key":"67336","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09894.x","DOI":"10.1111\/j.1365-2133.2010.09894.x"},{"key":"67337","doi-asserted-by":"crossref","unstructured":"Akta\u015f Karabay E, Kar\u015f\u0131yakal\u0131 N, Karabay E. Evaluation of sexual functions in female rosacea patients: a prospective, case-control study. Int J Impot Res 2020; 32: 628-634.","DOI":"10.1038\/s41443-020-0275-z"},{"key":"67338","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41443-020-0275-z","DOI":"10.1038\/s41443-020-0275-z"},{"key":"67339","doi-asserted-by":"crossref","unstructured":"Baldwin HE, Harper J, Baradaran S, Patel V. Erythema of rosacea affects health-related quality of life: results of a survey conducted in collaboration with the National Rosacea Society. Dermatol Ther 2019; 9: 725-734.","DOI":"10.1007\/s13555-019-00322-5"},{"key":"67340","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-019-00322-5","DOI":"10.1007\/s13555-019-00322-5"},{"key":"67341","doi-asserted-by":"crossref","unstructured":"Beikert FC, Langenbruch AK, Radtke MA, Augustin M. Willingness to pay and quality of life in patients with rosacea. J Eur Acad Dermatol Venereol 2013; 27: 734-738.","DOI":"10.1111\/j.1468-3083.2012.04549.x"},{"key":"67342","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04549.x","DOI":"10.1111\/j.1468-3083.2012.04549.x"},{"key":"67343","doi-asserted-by":"crossref","unstructured":"Woo YR, Lim JH, Cho DH, Park HJ. Rosacea: molecular mechanisms and management of a chronic cutaneous inflammatory condition. Int J Mol Sci 2016; 17: 1562.","DOI":"10.3390\/ijms17091562"},{"key":"67344","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/ijms17091562","DOI":"10.3390\/ijms17091562"},{"key":"67345","doi-asserted-by":"crossref","unstructured":"Bewley A, Fowler J, Sch\u00f6fer H, Kerrouche N, Rives V. Erythema of rosacea impairs health-related quality of life: results of a meta-analysis. Dermatol Ther (Heidelb) 2016; 6: 237-247.","DOI":"10.1007\/s13555-016-0106-9"},{"key":"67346","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-016-0106-9","DOI":"10.1007\/s13555-016-0106-9"},{"key":"67347","unstructured":"Cresce ND, Davis SA, Huang WW, Feldman SR. The quality of life impact of acne and rosacea compared to other major medical conditions. J Drugs Dermatol 2014; 13: 692-697."},{"key":"67348","doi-asserted-by":"crossref","unstructured":"Yepes-Nu\u00f1ez JJ, Guyatt GH, G\u00f3mez-Escobar LG, P\u00e9res-Herrera LC, Chu AWL, Ceccaci R, et al. Allergen immunotherapy for atopic dermatitis: dystematic review and meta-analysis of benefits and harms. J Allergy Clin Immunol 2023; 151: 147-158.","DOI":"10.1016\/j.jaci.2022.09.020"},{"key":"67349","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2022.09.020","DOI":"10.1016\/j.jaci.2022.09.020"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/40053\/46575","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/40053\/46575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T10:04:45Z","timestamp":1719309885000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/40053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":137,"URL":"https:\/\/doi.org\/10.2340\/actadv.v104.40053","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}